DNA Repair Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global DNA Repair Drugs Market size is projected to record an 8.9% CAGR from 2024 to 2032, driven by aging population. Cellular damage and genetic mutations have become more common in aging population, leading to an increased focus on therapies that can enhance DNA repair mechanisms. Researchers are developing and refining drugs to target specific pathways involved in maintaining genomic stability and repairing damaged DNA. To that end, DNA repair drugs are favored for preventing age-related diseases and improving cellular function. According to WHO, by 2030, 1 in 6 people globally will be aged 60 years or over. This demographic shift is driving increased interest in DNA repair drugs to address age-related genetic damage and enhance health and longevity.

The overall market is segregated into drug type, application, route of administration, distribution channel, and region.

In terms of drug type, the rucaparib segment in the DNA repair drugs market may experience significant growth by 2032, driven by its increasing role in targeting the inhibition of poly (ADP-ribose) polymerase (PARP) enzymes. By inhibiting PARP, rucaparib helps to prevent cancer cells from repairing their DNA, leading to cell death, particularly in cancers with existing DNA repair deficiencies, such as BRCA-mutant tumors. Ongoing research is exploring its effectiveness in treating various cancers and optimizing treatment regimens.

By application, the DNA repair drugs industry value from the fallopian tube cancer segment is projected to rise from 2024 to 2032, driven by increasing adoption for targeting specific genetic defects in cancer cells. The ongoing development is ensuring that therapies are targeting the unique genetic profiles of fallopian tube cancer, potentially leading to more personalized and successful treatments. This approach is making significant strides in improving outcomes for patients and will be increasingly integral in managing fallopian tube cancer.

Regionally, the Asia Pacific DNA repair drugs market size is projected to exhibit robust growth between 2024 and 2032, fueled by the rising incidence of genetic disorders. DNA repair drugs are currently being developed to address the increasing prevalence of genetic mutations that lead to various health conditions. By targeting specific genetic abnormalities, DNA repair therapies are enhancing treatment options and offering new hope for managing genetic disorders in the region.

Product Code: 10274

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of cancer
  - 3.2.1.2 Advancements in precision medicine
  - 3.2.1.3 Supportive government policies, grants, and funding for research and development
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulatory requirements for drug approval
  - 3.2.2.2 High development costs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 GAP analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Olaparib
5.3 Rucaparib
5.4 Niraparib
5.5 Talazoparib
5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Ovarian cancer
6.3 Fallopian tube cancer
6.4 Peritoneal cancer
6.5 Breast cancer
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 AstraZeneca Plc
10.2 AbbVie
10.3 Artios Pharma Limited
10.4 Breakpoint Therapeutics
10.5 ClovisOncology Inc.
10.6 FoRx Therapeutics
10.7 GlaxoSmithKline plc.
10.8 Johnson and Johnson
10.9 Luciole Pharmaceuticals
10.10 Merck KGaA
10.11 Onxeo
10.12 Pfizer Inc.